- Home
- DOW vs ROIV Comparison
DOW vs ROIV Comparison
Compare DOW & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOW | ROIV |
|---|---|---|
| Founded | 1897 | 2014 |
| Country | United States | United Kingdom |
| Employees | 35700 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8B | 23.2B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOW | ROIV |
|---|---|---|
| Price | $29.88 | $33.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $39.13 | $28.94 |
| AVG Volume (30 Days) | ★ 10.3M | 4.4M |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,968,000,000.00 | $8,260,000.00 |
| Revenue This Year | $5.40 | N/A |
| Revenue Next Year | $2.33 | $744.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.40 | $10.90 |
| 52 Week High | $42.74 | $37.00 |
Technical Indicators
Market Signals| Indicator | DOW | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 45.89 |
| Support Level | $28.72 | $26.65 |
| Resistance Level | $35.51 | $35.70 |
| Average True Range (ATR) | 1.03 | 1.11 |
| MACD | 0.22 | -0.33 |
| Stochastic Oscillator | 48.11 | 24.65 |
Price Performance
Historical ComparisonAbout DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in consumer and industrial end markets.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.